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The immune system can recognize and attack cancer cells, especially those with a high load
of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair
(MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/
deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing
translational frameshifts. Here, we develop a tool to quantify frameshift mutations in MSI
colorectal and endometrial cancer. Our results show that frameshift mutation frequency is
negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting
counterselection of cell clones with highly immunogenic frameshift peptides. This correlation
is absent in tumors with Beta-2-microglobulin mutations, and HLA-A*02:01 status is related to
cMS mutation patterns. Importantly, certain outlier mutations are common in MSI cancers
despite being related to frameshift peptides with functionally confirmed immunogenicity,
suggesting a possible driver role during MSI tumor evolution. Neoantigens resulting from
shared mutations represent promising vaccine candidates for prevention of MSI cancers.
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DNA mismatch repair (MMR) deficiency is a majormechanism causing genomic instability in human cancer.MMR-deficient cancers accumulate an exceptionally high
number of somatic mutations. These mutations encompass cer-
tain types of single-nucleotide alterations but mostly insertion/
deletion (indel) mutations at repetitive sequence stretches termed
microsatellites (microsatellite instability (MSI))1,2.
About 15% of colorectal cancers (CRCs), up to 30% of endo-
metrial cancers (ECs) and multiple other tumors display the MSI
phenotype3. MSI tumors can develop sporadically or in the
context of Lynch syndrome, the most common inherited cancer
predisposition syndrome. Due to this very specific process of
genomic instability, the pathogenesis of MSI cancers can be
precisely dissected4: indel mutations of coding microsatellites
(cMSs), which almost exclusively affect coding mononucleotide
repeats5–7, in genomic regions encoding tumor-suppressor genes
are considered major drivers of MSI tumorigenesis. Importantly,
the same indels that inactivate tumor-suppressor genes simulta-
neously cause translational frameshifts, thereby generating unique
frameshift peptides as a major source of neoantigens4,8.
For the recognition of neoantigens by the immune system,
processing through the cellular antigen processing machinery and
presentation by human leukocyte antigen (HLA) class I molecules
on the tumor cell surface are essential prerequisites. These HLA
class I molecules consist of a heavy chain and a non-covalently
bound light chain (encoded by the Beta-2-microglobulin [B2M]
gene), both of which are essential for functional antigen pre-
sentation. The likelihood of HLA binding for a defined peptide
depends on the HLA genotype, as every individual harbors six
alleles (HLA-A, HLA-B, HLA-C, two alleles each) that encode for
HLA class I heavy chains9.
The specific mutational steps required for malignant trans-
formation during the evolution of MSI tumors are thus also
responsible for their pronounced immunogenicity. MSI tumors
are commonly associated with dense lymphocyte infiltration and
pronounced local responses of the adaptive immune system at the
tumor site10–14. Immune recognition of MSI tumor cells is not
only responsible for a comparatively favorable clinical course but
also reflected by the high sensitivity of advanced-stage MSI
cancers toward immune checkpoint blockade (ICB)15,16. How-
ever, some patients do not respond to ICB treatment.
We and others previously showed that specific T cell responses
against a few MMR deficiency-induced frameshift neoantigens
occur prior to and after ICB15,17,18. However, the landscape of
frameshift peptides and potential epitopes in MSI cancer has not
been described systematically. One important reason for this gap
of knowledge is the fact that short-read next-generation
sequencing (NGS) approaches have a limited sensitivity for the
detection of indel mutations at homopolymer sequences such as
frameshift peptide-inducing cMS19–21.
Here we map the frameshift peptide landscape of the two most
common MMR-deficient cancer types, CRC and EC, using a tool
for the quantification of cMS mutation patterns (ReFrame,
REgression-based FRAMEshift quantification algorithm) com-
bined with NetMHCpan 4.0, a state-of-the-art in silico epitope
prediction tool9. We reveal and functionally validate a set of
previously unknown shared frameshift neoantigens in MSI
cancers.
Our results provide evidence for continuous immunoediting
during MSI tumor evolution and underline the potential of
neoantigen-based vaccines against MSI cancers.
Results
cMS mutation frequencies in MSI CRC and EC. Short-read
NGS approaches are not ideally suited for mutational and
frameshift peptide profiling of MSI cancers19–21, showing a high
variability in mutation frequency regarding the detection of
mutations in different cMS candidates like those located in the
genes TGFBR2, SLC35F5, or TFAM (Supplementary Table 1).
Importantly, cMS repeats of increased length, which are most
susceptible to mutations and therefore encompass the most
important mutational targets during MMR-deficient tumorigen-
esis, are missed by NGS technology that is in common use
today3,5,19,22–26.
To fill this gap and precisely quantify cMS mutation patterns
and their resulting translational reading frames in MMR-deficient
cancers, we developed an algorithm based on fragment length
analysis as the current gold standard for the detection of MSI.
ReFrame, our REgression-based FRAMEshift quantification
algorithm, allows unbiased quantitative detection of indel
mutations by solving a linear system of mathematical equations
to remove stutter band artifacts, which result from polymerase
slippage events during PCR amplification and subsequent
nucleotide gains and losses similar to MSI-induced indels
(Supplementary Fig. 1).
We used ReFrame in a series of MSI CRCs (n= 139; Supple-
mentary Table 2) to screen for mutations in 41 cMS residing in 40
target genes derived from the first comprehensive cMS database
(SelTarbase, Version 201307)27. In addition, we investigated
mutation profiles in a cohort of MSI ECs (n= 28).
In agreement with previous reports23,27, our results show that
the load of indels at cMS in MSI CRC and EC is high and that
multiple concomitant indels at several cMS in the same tumor are
very common. Although most CRCs and ECs were distinguish-
able based on the cMS mutation patterns, a large set of cMS
mutations were shared by the majority of MSI CRCs and/or MSI
ECs (Fig. 1 and Supplementary Fig. 2).
Moreover, we observed a significant variation of the number of
mutations per tumor, ranging from 8 to 29 (median: 20) out of 41
analyzed cMS in MSI CRC and from 8 to 25 in MSI EC (median:
18). The observed variation suggests potential differences in the
frameshift peptide load of MSI tumors. Potential clinical
consequences, e.g., for the sensitivity toward ICB, should be
assessed in future clinical studies28–30.
ReFrame is not only able to quantify mutation frequency but
also to distinguish indel mutation types, which is crucial for the
prediction of the frame of the resulting frameshift peptides. As
the translation of nucleotide into amino acid sequences is based
on three base codons, every mutation in a homopolymer region
can either result in a simple deletion or insertion of amino acids
or in two entirely different frameshift peptide reading frames:
deletions of one nucleotide (further referred to as minus 1 (m1))
or insertions of two nucleotides (plus 2 (p2)) will result in a shift
to a frame here referred to as minus one (M1), while deletions of
two nucleotides (minus 2 (m2)) or insertions of one nucleotide
(plus 1 (p1)) will result in a shift to a frame referred to as minus
two (M2) (Fig. 2, Supplementary Fig. 3, and Supplementary
Table 3). The results demonstrate that m1 mutations, resulting in
M1 reading frames, were the predominant mutation type (77% in
MSI CRC, Fig. 2). The M1/M2 distribution varied significantly
across distinct cMS, with significantly elevated numbers of M2
mutations in BANP, TAF1B, and ELAVL3, whereas in ACVR2A,
HPS1, SLC35F5, and TCF7L2 there were significantly more
mutations leading to an M1 frameshift than expected by chance
(Bonferroni corrected binomial test, p < 0.05; Supplementary
Table 4).
Landscape of frameshift peptides and predicted major histo-
compatibility complex (MHC) ligands. Following the detection
of shared indel mutations in MSI CRC and EC, we evaluated the
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immunogenic potential of the frameshift peptides and predicted
MHC ligands resulting from antigen processing.
We used NetMHCpan 4.0, a state-of-the-art MHC ligand
prediction tool based on artificial neural networks, to predict
neopeptides that are possibly presented as epitopes by HLA class I
antigens encoded by the most important HLA supertypes9,31,32.
Applying commonly accepted IC50 thresholds, we distinguished
between three classes of peptides with high (IC50 < 50 nM), low
(50 nM < IC50 < 500 nM), and very low (500 nM < IC50 < 5000
nM) predicted HLA-binding affinity31,33. As a first step, we
analyzed all possible frameshift peptide sequences derived from
the M1 and M2 frameshifts of the 41 cMS. We then
complemented this set to cover all possible frameshift peptides
(n= 524) derived from 264 cMS with a length of ≥8 nucleotides
published in SelTarbase (Supplementary Data 1)27. Our results
indicate multiple frameshift peptides resulting from M1 or M2
frameshift mutations that are potentially recognized by the
immune system. We detected a wide range of variability with
regard to the number of predicted putative epitopes maximally
contained within a defined frameshift peptide. The highest
number of predicted putative high-affinity epitopes within a
frameshift peptide was 23 (for the M1 frame of P4HB), (low
affinity: 92 predicted putative epitopes in M1 SPINK5; very low
affinity: 375 predicted putative epitopes in M1 P4HB). Other cMS
mutation-induced frameshift peptides showed a complete lack of
the predicted epitopes (Fig. 3 and Supplementary Data 2).
For HLA-A*02:01, the most common HLA allele in the USA
European Caucasian population34, one or more high-affinity
peptides were predicted for 19.8% of the frameshift peptides.
HLA-A*02:01 epitopes with lower affinity were present in 39.5%
(≤500 nM) and 59.7% (≤5000 nM) of candidates (Supplementary
Fig. 4 and Supplementary Table 5. Plots depicting predicted
HLA-binding peptides for all frameshift peptides and HLA alleles
are available in the Source Data folder.).
To make the potential impact of certain cMS candidates more
tangible and to identify frameshift peptides with potentially
highest relevance for immune recognition, we defined a general
epitope likelihood score (GELS; see “Methods” section “Compu-
tation of immunological scores”). GELS accounts for MHC ligand
prediction and the prevalence of the respective HLA allele in a
defined population, as the latter influences the probability of a
frameshift peptide to encompass an MHC ligand recognized by
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Fig. 1 Mutation frequencies of cMS in MSI CRC and EC. a The relative frequency of mutant alleles is shown for 41 cMS (rows) in CRC and EC tumor
samples (columns) derived using ReFrame. cMS were sorted top–down according to their mutation frequency indicated by blue boxes of different intensity.
Dark blue represents high mutation frequency, whereas pale blue represents low mutation frequency and white absence of mutations. Black boxes indicate
missing data points. The respective tumor samples are shown below each column. cMS were analyzed for both CRC and EC and are depicted separately for
each tumor type (left panel: CRC, right panel: EC). The complete dataset is provided in Supplementary Fig. 2. Source data for Supplementary Fig. 2 are
provided as a Source Data file. b Dendrogram of CRC and EC samples with respect to their mutation patterns where the color bar below indicates the
tumor type (CRC, blue; EC, red). c Principal component analysis of EC (red) and CRC (blue) samples with respect to their mutation patterns.
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cMS MSI colorectal cancers (CRC); n = 139 MSI endometrial cancers (EC); n = 28
Gene name
BANP
Type Length %mut %wt<0.5 m3 m2 m1 wt p1 %mut %wt<0.5 m3 m2 m1 wt p1
BANP
n = 124 n = 120 n = 137 n = 123 n = 113 n = 127 n = 125 n = 121 n = 111 n = 107
n = 28 n = 24 n = 24 n = 27 n = 28 n = 26 n = 27 n = 25 n = 27 n = 27
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Fig. 2 Mutational pattern distribution in cMS based on ReFrame analysis. a Scheme of frameshift mutations (m3, m2, m1, wt, p1, p2) on the left and their
corresponding frames (M0, M1, M2) on the right. The numbers 1–3 indicate base triplets in the corresponding frame. Arrows mark the shift between the wt
frame and the alternate frame. b Distribution of all cMS frameshift mutations (m3–p2) and their corresponding frames (M0, M1, M2) in MSI CRC
quantified using ReFrame. Mutations in all MSI CRC samples were classified in corresponding reading frames (M0, black; M1, magenta; M2, green) and
their overall allele ratios quantified. c The detailed mutational patterns of ten representative cMS are depicted with their respective frequency of mutation
for all possible resulting frameshift mutations (m4–p4) in MSI CRC and EC (see Supplementary Fig. 3 for complete dataset). Each row constitutes one
analyzed tumor sample with its related allele ratios. For each cMS, tumors were sorted by the proportion of wild-type alleles top to bottom. The number of
samples analyzed for a certain candidate is indicated below each candidate’s figure. Color indicates the resulting reading frames as in b. Intensities
represent ReFrame-calculated ratios from white (0%) to full-intensity magenta/green/black (100%) according to the resulting reading frame of the
column. The annotated solid lines (first horizontal line top down) show the end of the non-mutated tumor samples (cutoff: 15%), while the dotted lines
(second horizontal line top–down) mark the beginning of tumors being >50% mutated, associated with biallelic hits within the respective sample. Source
data are available as a Source Data file. d Calculated mutation frequencies and mean allele ratios of most common indel mutation types (m3–p1) resulting
from ReFrame analysis in ten representative cMS candidates sorted by length. %mut proportion of mutant tumors, %wt<0.5 proportion of tumors with
biallelic hits. Columns m3–p1 display average frequencies of the respective indel mutations over all the samples tested.
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the immune system in a patient of this population9,34. We
calculated GELS for all frameshift peptides using HLA allele
frequencies for USA European Caucasians (calculations for
additional ethnic groups are provided in Supplementary Data 3).
Accounting for a potential relation between immunogenicity
and mutation frequency, we noticed that the most commonly
mutated cMS located in the ACVR2A gene showed a very low
GELS (pmut= 91%, GELS= 5.1%), whereas very high GELS
candidates seemed to be associated with a low mutation
frequency (i.e., TMEM97, pmut= 27%, GELS= 91.1%; SPINK5,
pmut= 26%, GELS= 91.1%; RUFY2, pmut= 16%, GELS= 90.4%;
pbinding= 50% in USA European Caucasian population; Supple-
mentary Data 3). Hierarchical clustering of cMS candidates on all
tumor samples revealed the existence of three distinct populations
of cMS (Fig. 4a), which was retained in B2M-wild-type (n= 99)
but not in B2M-mutant (n= 33) tumors (Fig. 4b).
Immunoselection during MSI carcinogenesis. In order to sys-
tematically evaluate whether these observations may result from
immunoediting, i.e.., counterselection of emerging cancer cell
clones that harbor highly immunogenic cMS mutations (high
GELS frameshift peptides), we analyzed potential differences
between the observed and expected distribution of cMS muta-
tions, first in an HLA type-independent approach. Already here
we observed a significant inverse correlation between GELS and
mutation frequency with Pearson’s r=−0.45, p= 0.0078 at n=
41 cMS for endometrial tumors and r=−0.42, p= 0.0149 for
colon tumors, with a conservative estimate of predicted HLA-
binding probability of pbinding= 50%, indicating that a high GELS
was related to lower mutation frequency (Fig. 4c). The correlation
remained significant even at the lowest epitope fidelity levels of
pbinding= 10%, with p= 0.0145 for endometrial and p= 0.0031
for colon cancers.
The observation suggests that emerging tumor cell clones with
highly immunogenic frameshift peptides are counterselected
(Fig. 5), showing that immunoediting may leave its traces in
frameshift peptide/cMS mutation patterns in MSI cancers35–38.
Interestingly, the significant inverse correlation was only detected
among B2M-wild-type tumors. B2M-mutant tumors, in which
immune selection on the basis of HLA class I antigen
presentation should not apply, only a trend was observed
(Fig. 4d), which possibly reflects effects of immune surveillance
prior to B2M mutation. To account for confounding factors
potentially influencing this observation, we investigated a
potential relationship between the cMS length and our observed
negative correlation. cMS length is a well-known factor influen-
cing the likelihood of indel mutations on the observed mutation
frequency23,27,39 (Supplementary Fig. 5). However, our analysis
demonstrated that GELS was not related to the length of the
corresponding microsatellite. Moreover, we replicated the corre-
lation analysis with length-adjusted relative mutation frequencies
(relative pmut, computed by subtracting the length-specific M1
average mutation frequency from the observed M1 mutation
frequency for each microsatellite), the negative correlation
between GELS and relative mutation frequency in B2M-wild-
type tumors was retained (Supplementary Fig. 8a, b).
In order to specifically address HLA-type dependence of
immunoediting, HLA-A*02:01 status was determined in MSI
CRC and EC40,41. HLA-A*02:01 was present in 34 (47.9%) of 71
MSI CRC and 13 (47.1%) of 27 MSI EC samples, in line with
proportions reported for German populations (prevalence of
HLA-A*02:01: 46.2%, n= 39,689, www.allelefrequencies.net). A
significant negative correlation (Pearson’s r=−0.15, p < 0.001)
was observed between cMS mutation frequency and the like-
lihood of HLA-A*02:01 ligands resulting from the respective cMS
mutation in the HLA-A*02:01-positive but not in the HLA-
A*02:01-negative group of MSI CRC (Fig. 5a). Interestingly, this
significant HLA-A*02:01-restricted negative correlation was also
observed in MSI EC (Fig. 5b), independently supporting the
concept of HLA class I-related immunoediting of MSI tumors in
the colorectum and endometrium. Again, replication of the
analysis using relative mutation frequencies confirmed the
negative correlations (Supplementary Fig. 8c).
Despite the statistically significant negative correlation
between GELS and mutation frequency, we also observed some
outliers (Fig. 4c). We hypothesize that these outliers may reflect
distinct effects that potentially influence the probability of a
certain cell clone harboring a defined mutation to survive and
thrive during tumor evolution. In addition to potential
enhancement of immunogenicity, cMS mutations in tumor-
suppressor genes are predicted to lead to a growth advantage, at
least in cancer or pre-cancer cell clones not directly under































# Overlapping binding peptides (M1)
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# Overlapping binding peptides (M2)
Fig. 3 MHC ligand predictions for a dataset of 82 analyzed frameshift peptides. The figures display the predicted epitopes for the M1 and M2 frameshift
peptides derived from all 41 cMS candidates over the length of the respective peptide. All epitopes predicted for three binding affinity thresholds (IC50 <
50 nM, IC50 < 500 nM, and IC50 < 5000 nM) are shown for the M1 frameshift peptides (left, magenta) and the M2 frameshift peptides (right, green). All
candidates are sorted in alphabetical order with their respective frequency of mutation according to the ReFrame results. The gray field represents
background and indicates C-terminal ends of the respective frameshift peptides.
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attack of the immune system. Such cMS candidates with high
GELS and mutation frequencies should be of great relevance for
the interaction between the immune system and MMR-
deficient tumor cells. To simultaneously account for mutation
frequency and GELS as factors influencing the likelihood of
frameshift peptides being presented to the immune system, we
defined an immune relevance score (IRS), which combines
GELS with the mutation frequency in tumors computed via
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Fig. 4 Evidence of immune selection from cMS mutation patterns and GELS. a Hierarchical clustering of cMS candidates on all tumor samples using
frameshift abundance features. The full clustering hierarchy is displayed as a dendrogram, showing three clusters (yellow, blue, pink). The same clusters
are visualized using RBF kernel PCA with two principal components and colored by their GELS. The three clusters display a trend in their mean GELS, with
increasing values from pink to blue to yellow. b Hierarchical clustering of cMS on features split by B2M status, with wild type at the top and mutated at the
bottom. The full hierarchy is displayed as a dendrogram for both feature sets. In contrast to B2M wild type, B2M-mutated features show no clustering at the
computed clustering dissimilarity threshold of 5.7. The same data are again shown using RBF kernel PCA with two principal components. c Mutational
frequency resulting from one base pair deletions (m1) is shown on the y axis against the GELS of the resulting M1 frameshift peptides (x axis). For GELS, all
predicted epitopes (IC50 < 500 nM) were accounted for, with an assumed probability for a binder to be a true positive of pbinding= 50%. Every bubble
represents one candidate. The gradient intensity of the bubbles shows IRS, with white color representing a low IRS, while dark red displays a high IRS. All
candidates with an IRS of ≥10% are annotated. d Correlation between the number of predicted epitopes in cMS mutation-induced frameshift peptides and
the frequency of the respective cMS mutations in MSI colorectal cancer separated by B2M mutation status. Pearson’s r is shown on the y axis, while the
different groups of tumors are shown on the x axis. Centers indicate Pearson’s r, whiskers indicate 95% confidence intervals. A significant inverse
correlation was observed showing r=−0.42, p= 0.0149 at n= 41 candidates for 99 MSI colorectal cancers with wild-type B2M, with a conservative
estimate of predicted epitope fidelity of pbinding= 50%, indicating that high GELS was related to lower mutation frequency (for analysis of relative mutation
frequencies, see also Supplementary Fig. 8).
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The M1 frameshift neoantigen derived from TGFBR2, the first
described cMS driver mutation in MSI cancer and also the first
ever frameshift neoantigen characterized for its immunological
properties in MSI cancer in pioneering studies18,42,43, displays the
highest IRS (28.57%). In addition to this well-characterized
frameshift neoantigen, our study uncovered various frameshift
peptide candidates with predicted importance for the immune
biology of MMR-deficient cancers. The candidates LTN1,
SLC22A9, SLC35F5, CASP5, TTK, TCF7L2, MYH11, MARCKS
(all M1), and BANP (M2) all displayed an IRS >10% (Fig. 4c and
Supplementary Data 3). The spatial distribution of predicted
MHC ligands within these high-IRS frameshift peptides is
visualized in Supplementary Fig. 6.
To validate the immunogenicity of the predicted HLA-
A*02:01-restricted epitopes, HLA-A*02:01-transgenic mice44
were vaccinated with the respective frameshift peptides. Here
interferon gamma (IFNɣ) ELISpot demonstrated reactivity
corresponding to HLA-A*02:01 epitope prediction for 8 out of
9 tested candidates, confirming processing and presentation of
frameshift peptide-derived HLA-A*02:01 ligands for 6 out of 7
candidates (LTN1, SLC35F5, TGFBR2, SLC22A9, TTK, MYH11;
Fig. 5c). For CASP5, processing and presentation of HLA-
A*02:01-restricted epitopes had been proven previously45.
Interestingly, candidate genes with a possible tumor-suppressor
function were common among the high-IRS genes: CASP5
(apoptosis induction; IRS: 17.15%), TTK (maintenance of
chromosomal stability; IRS: 12.38%), TCF7L2 (beta-catenin
signaling; IRS: 11.32%), MYH11 (cell structure and proliferation;
IRS: 11.11%), and BANP (migration and invasiveness; IRS:
10.73%) were all previously reported in the literature46–54.
This observation may suggest that highly immunogenic frame-











# of predicted HLA-A*02:01-binding epitopes 









































































































0 0 0 4 4 7 7 10 12 13 19
Fig. 5 HLA-A*02:01-specific analyses. Correlation between the probability of at least one putative binder truly binding to HLA-A*02:01 within an M1
frameshift peptide and the respective M1 mutation rate in B2M-wild-type HLA-A*02:01-positive and HLA-A*02:01-negative CRC (a) and EC (b). The
Pearson’s r from the correlation test is shown on the y axis, while the different groups of tumors are shown on the x axis. Centers indicate Pearson’s r,
whiskers indicate 95% confidence intervals. A highly significant inverse correlation was observed showing r=−0.15, p= 4.4 × 10−16 at n= 34 HLA-
A*02:01-positive CRCs with all parameters kept from Fig. 4d. For n= 37 HLA-A*02:01-negative CRCs (other), significance did not persist at p= 0.29.
Similarly, a significant inverse correlation between HLA-A*02:01-binding scores and mutation frequency was detected for HLA-A*02:01-positive MSI EC
(n= 13, r=−0.15, p= 0.00002) but not for HLA-A*02:01-negative MSI EC (n= 14) (see also Supplementary Fig. 8c, d). c Cellular immune response of
M1 frameshift peptides in HLA-A*02:01-expressing A2.DR1 mice. IFNɣ ELISpot was performed with splenocytes from immunized A2.DR1 mice (n= 3) re-
stimulated with the respective, specific M1 frameshift peptides LTN1, MARCKS, SLC22A9, SLC35F5, MYH11, TTK, TCF7L2, CASP5 (magenta), irrelevant
peptide (green), or no peptide (black) as controls. Long frameshift peptides SLC22A9 and MYH were synthesized in two parts (split frameshift peptides
are marked by asterisks), with the N-terminal peptide labeled 1 and the C-terminal peptide labeled 2. Each dot represents the number of IFNɣ spots per 1 ×
106 cells for one mouse. Mean values are indicated by horizontal lines. The M1 frameshift peptides are sorted according to the number of predicted HLA-
A*02:01 ligands (IC50 < 500 nm). Source data are available as a Source Data file.
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compensatory survival advantage from the mutation by switching
off a tumor-suppressive pathway, supporting their role of
propelling MSI tumor evolution (Fig. 6 and Supplementary
Fig. 9).
Discussion
MMR-deficient tumors, due to their well-defined mechanism of
genomic instability, represent an ideal tumor type to study the
evolution of solid cancer development and the role of the immune
system during this process. By analyzing a broad spectrum of
cMS-encompassing genes that are susceptible to mutation in
MMR-deficient cells, we were able to identify recurrent mutations
and frameshift peptides and to provide first evidence suggesting
immunoediting during MSI cancer development.
The results of our study demonstrate that, in contrast to
neoantigens in many other cancer types, which typically differ
between tumors or even occur as “private” mutational neoanti-
gens, MMR-deficient cancers share a large pool of frameshift
peptides: the dominance of alterations of the M1 type resulting
from one-base pair deletions (m1) emphasizes that MMR-
deficient cancers not only share similar sets of genes inactivated





























































Fig. 6 Influence of immunoediting on cMS mutation patterns in MSI CRC. a Coding mononucleotide mutations in MSI cancer can lead to the inactivation
of tumor-suppressor genes and therefore have a driver effect on tumor development. Simultaneously, the same mutations can trigger the generation of
frameshift peptides with a certain immunogenicity. In the scheme, cMS are located in a two-dimensional lattice depending on the strength of the driver
effect resulting from a cMS mutation (y axis) and the immunogenicity of the respective frameshift peptide (x axis). Color illustrates cMS mutation
frequency, with dark blue representing high mutation frequency and white absence of mutations (according to heat map in Fig. 1a). The combination of
positive selection (blue arrows) and negative selection (white arrows) pressure in B2M-wild-type tumors leads to highest frequencies for non-
immunogenic driver cMS mutations and lowest frequencies for immunogenic non-driver cMS mutations (left panel). In B2M-mutant tumors, negative HLA
class I-dependent selection is absent; therefore, expected mutation frequencies are independent from immunogenicity of frameshift peptides. b Scheme of
MSI CRC evolution. B2M mutation can occur as a mechanism of immune evasion during tumor progression. B2M mutations lead to a breakdown of HLA
class I-mediated antigen processing and therefore interferes with T cell-mediated elimination of MSI cell clones harboring immunogenic frameshift
peptides (also see Supplementary Fig. 9).
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same frameshift peptides resulting from these mutations, allowing
the definition of a shared frameshift peptide set for MMR-
deficient cancers.
Using NetMHCpan 4.0, we predicted a large set of potential
MHC ligands in shared frameshift peptides. This number may
even increase when using looser prediction thresholds, as
recommended in a recent study evaluating the performance of
MHC ligand prediction tools55–57. Although many frameshift
peptides do not encompass such ligands for any of the common
HLA types, our calculations demonstrate that the vast majority of
MSI cancers are predicted to generate one or more frameshift
peptides potentially recognizable by the host’s immune system.
Validity of positive and negative predictions of HLA-A*02:01
ligands could be proven for eight out of nine shared frameshift
peptide candidates. The immunological relevance of mutation-
induced frameshift peptides is further supported by the obser-
vation of common frameshift peptide-specific T cell responses in
patients with MSI cancer and Lynch syndrome mutation car-
riers8. Several of the frameshift peptides derived from common
cMS mutations encompass hot spot sequences for which multiple
MHC ligands have been predicted (indicated by dark colors in
Fig. 3), suggesting that these might be of increased interest for
further evaluation56,57.
By combining quantitative cMS mutation analysis with a spe-
cific immune score that accounts for the prevalence of the
respective ligand-binding HLA molecules in the population, we
identified patterns in the cMS mutation spectrum of MSI cancers
suggestive of immune selection: candidates that encompass
immunogenic epitopes predicted to bind to common HLA types
tend to occur less frequently in manifest MSI cancers. This could
be confirmed specifically in HLA-A*02:01-positive patients
whose tumors, CRC and EC alike, presented significantly less
mutations giving rise to predicted HLA-A*02:01 ligands than
expected in a neutral scenario. Our observations support the
concept that immune surveillance is a major force shaping the
natural course of MMR-deficient cancer development4,25,26,37,58.
Depletion of expressed neoantigens, similar to what our data
suggest, has recently also been reported in lung cancer59.
Interestingly, mutation patterns suggestive of HLA class I-
dependent immunoediting were only observed in B2M-wild-type
tumors. This encourages further studies that systematically
address the effects of other immune evasion mechanisms such as
alterations of HLA class I heavy chains or components of the
antigen-processing machinery37 on antigen landscapes in MSI
cancer.
Alternative GELS-independent reasons underlying the
observed relations between mutation frequency and predicted
immunogenicity do not appear likely. There is no evidence for
specific indel mutational signatures60 favoring the generation of
less immunogenic frameshift peptides in MMR-deficient cells,
because potential MHC-binding motifs in frameshift peptides are
generally located downstream and independent of the actual
mutation event. In addition, the median GELS of frameshift
peptides resulting from indels affecting A/T repeats (0.617) was
virtually identical to the one related to G/C repeats (0.615), fur-
ther arguing against a signature-related bias. Moreover, an arti-
ficial nature of the observed mutations, for example, resulting
from formalin fixation, can largely be excluded, because formalin
fixation-induced artifacts mostly represent C>T alterations with a
limited allele frequency61, and measures were taken to minimize
potential artifacts, including use of buffered formalin, limited
fixation times, and preparation of large amounts of template
DNA for each tumor.
Another factor potentially influencing the immunological
consequences of cMS mutations in MMR-deficient cancers is
nonsense-mediated RNA decay (NMD). NMD is known to
differentially affect the degradation of target mRNAs in MSI
tumors62–64. Mutant mRNAs that escape NMD surveillance are
expected to account for the high frameshift peptide load in MSI
tumor cells. Although NMD may interfere with the translation of
mutant mRNAs into frameshift peptides, complete elimination of
NMD-sensitive mutant mRNAs by NMD is rare62–64, and even
degradation of NMD-sensitive, mutant mRNAs does not entirely
preclude T cell responses specific for the respective
neopeptides65,66. Systematic studies analyzing the effect of NMD
on the antigen spectrum and immune surveillance in MSI tumors
are warranted.
Other studies failed to detect evidence for negative selection of
immunogenic, neoantigen-inducing mutations in cancer and
thereby immunoediting67,68. This discrepancy may be related to
the fact that the present study addressed frameshift peptides
derived from indel mutations, whereas point mutation-induced
antigens were examined in the other studies67,68. Moreover,
ReFrame allows to distinguish between M1 and M2 frames
resulting in entirely different frameshift peptides, thus providing
the resolution required for distinguishing the entirely different
immunological consequences of mutations causing an M1 or M2
frameshift. Our study also accounts for the population frequency
of defined HLA types and provides specific information about
HLA type of patients studied. In general, the detectability of
specific counterselection events is supported by three specific
features of MMR deficiency: first, MMR-deficient cancers in
contrast to other tumors share precisely the same mutations,
because the location of a cMS within a gene determines its sus-
ceptibility for indel mutations in MMR-deficient cells; second,
MMR-deficient cancers due to the dramatically elevated rate of
somatic mutations per cell division are expected to harbor a
significantly higher proportion of MMR deficiency-induced
mutations compared to age-related mutations that have occur-
red prior to tumor initiation, thus enhancing the visibility of
negative selection events; third, counterselection against frame-
shift peptides may be particularly pronounced, as MMR
deficiency-induced mutations often lead to generation of long
frameshift peptides with potentially multiple epitopes, against
which no central immune tolerance exists69.
The observation of HLA-A*02:01-dependent immunoediting
during the development of MMR-deficient cancers also implies
that a person’s HLA genotype may have an influence on the
immune environment during MSI tumor evolution. Given the
existence of immune-relevant frameshift peptides that may be
bound only by a certain type of HLA molecules, it is reasonable to
assume that HLA genotype may be a modifier of cancer risk. This
may also explain possible variations of Lynch syndrome pene-
trance or different rates of MMR deficiency previously suspected
between distinct populations70. Future studies on the natural
course of Lynch syndrome should account for this factor.
Our study has the following limitations. The list of frameshift
peptides analyzed with ReFrame is not exhaustive. The 40
candidates analyzed in our study are derived from a compre-
hensive database encompassing 558,000 coding mononucleotide
repeats27, and mutation data provided by SelTarbase.org (Version
201307), which contain information about 4433 distinct mono-
nucleotide repeats from 616 studies, were used for candidate
selection. However, additional frameshift mutations resulting
from other, predominantly shorter and less frequently mutated
cMS can occur in MSI cancers. Because only paraffin-embedded
tissue was available from CRC and EC samples, HLA typing could
only detect absence or presence of HLA-A*02:01, restricting
HLA-related immunoediting analyses to HLA-A*02:01. In addi-
tion, we can only propose an atlas of predicted potential neoe-
pitopes in MSI cancers, and a possible influence of NMD could
not be systematically addressed. Although previous studies
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evaluated a few of the predicted candidates18,45, supporting the
general validity of the in silico predictions, functional validation
in our study was only feasible for HLA-A*02:01 ligand predic-
tions due to the availability of a suitable transgenic mouse
model44. Further studies are encouraged to directly detect fra-
meshift peptide-derived neoepitopes, e.g., by elution from HLA
class I complexes on the surface of MSI cancer cells.
The shared frameshift peptide landscape of MSI cancers
encourages preventive vaccines, particularly in the setting of
Lynch syndrome. If we are able to enhance the abundance of
T cells recognizing frameshift neoantigens by a specific vaccine,
we may shift the balance toward elimination of emerging cancer
cells, thereby reducing the likelihood of escape variants leading to
outgrowth of clinically manifest tumors. The safety and immu-
nological efficacy of such a frameshift peptide-based vaccine has
already been demonstrated in a first clinical phase I/IIa trial
(https://clinicaltrials.gov/show/NCT01461148). If the immune
system can be specifically sensitized toward frameshift neoanti-
gens resulting from driver mutations that inactivate tumor-
suppressor genes, such as the ones we evaluated in this study,
tumor evolution should be influenced in a way that outgrowth of
“dangerous” MSI cancer cell clones should become significantly
less likely.
In conclusion, frameshift mutation landscapes in MSI cancers
suggest negative selection of mutations that give rise to highly
immunogenic frameshift neoantigens. This supports the immu-
noediting concept in non-viral human tumors. Frameshift
peptide-based vaccination approaches for the prevention of
MMR-deficient cancers should account for the natural immune
surveillance during their development and focus on strengthening
the host’s immune response against neoantigens that are related
to essential driver mutation events.
Methods
Tumor specimens. Formalin-fixed, paraffin-embedded (FFPE) archival tissue
blocks were collected from 139 MSI CRCs and 28 MSI ECs. Pseudonymized clinical
data of each tumor patient is summarized in Supplementary Table 2. Tumors were
obtained from the Department of Applied Tumor Biology, University Hospital
Heidelberg in frame of the German HNPCC Consortium, the Finnish Lynch
syndrome registry, and Leiden University Medical Center. The study was approved
by the Institutional Ethics Committee, University Hospital Heidelberg. Informed
consent was obtained from all patients.
Tissue workup and DNA isolation. FFPE tumor sections (5 µm) were depar-
affinized and stained with hematoxylin and eosin according to standard proto-
cols58. DNA was isolated from tissue sections after separate microdissection of
normal and tumor tissue. Only samples with a tumor cell content of >80% were
used for the analysis. Genomic DNA was isolated using the Qiagen DNeasy Tissue
Kit (Cat. No. 69506, Qiagen, Hilden, Germany) according to the manufacturer’s
instructions.
MSI analysis. The tumors were characterized for their MSI status using the NCI/
ICG-HNPCC five microsatellite marker panel supplemented with additional
mononucleotide markers BAT40 and CAT2571. Tumors displaying instability in
>30% of the analyzed markers were classified as MSI.
Analysis of frameshift mutations in cMS. In order to amplify the cMS loci,
primers were either obtained from the SelTarbase (Version 201307, www.
seltarbase.org)27 or designed using the primer3 software (Primer3web version 4.0.0,
http://primer3.ut.ee/), with one primer of the primer set carrying a 5′ fluorescent
(fluorescein isothiocyanate) label. Primers were designed to generate amplicons in
range between 100 and 150 nucleotides for robust PCR amplification (Supple-
mentary Table 6). PCR was performed in a total volume of 5 µl containing 0.5 µl
10× reaction buffer (Invitrogen, Karlsruhe, Germany), 1.5 mM MgCl2, 200 mM
dNTP mix, 0.3 mM of each primer, 0.1 U Taq DNA polymerase (Invitrogen), and
10 ng of genomic DNA, using the following protocol: initial denaturation at 94 °C
for 5 min; 36 cycles of denaturation at 94 °C for 30 s, annealing at 58 °C for 45 s,
and primer extension at 72 °C for 1 min; final extension step at 72 °C for 7 min.
PCR fragments were separated on an ABI3130xl genetic analyzer (Applied Bio-
systems, Darmstadt, Germany). Generated raw data were analyzed using the
GeneMapper™ Software version 4.0 (ThermoFisher, Waltham, USA). Peak height
profiles were extracted and processed using ReFrame based on R version 3.4.3.
Microsatellite allele distributions analyzed using ReFrame. In general, PCR
amplification of microsatellite loci generates fragments that can vary in length,
either due to indel mutations in MMR-deficient cells or due to polymerase slippage
during amplification (stutter band artifacts). These two phenomena cause overlays
of peak patterns and hamper data interpretation. We developed ReFrame, a
REgression-based FRAMEshift quantification algorithm, to allow quantitative
analysis of microsatellite mutations by removing stutter band artifacts.
We obtained main peak fractions as a function of microsatellite length L, to
which a logistic function, in the following referred to as p(L), was then fitted. For
each microsatellite in question, an effective length was computed using that fit. We
then determined stutter fractions for each gene by calculating the ratios of
additional fragments occurring at each microsatellite locus in MMR-proficient
control samples (n= 20) to establish baseline reference values pref. For each cMS,
we computed the expected relative contributions of each indel in the range of Δ=
−4 deletion to Δ=+4 insertion to each band in the data as:
CLΔΔ0 ¼ I<5 Δ0  Δð Þ  pref Δ0  Δð Þ 
1 peffective L;Δð Þ
1 pref 0ð Þ
; ð1Þ
where we defined
peffective L;Δð Þ ¼ p p1 Lð Þ þ Δ
 
; ð2Þ
I<x yð Þ ¼
1; jyj< x
0; jyj ≥ x:

ð3Þ
We used these relative contributions to set up a linear system for the true peak size
without stutter contributions (Supplementary Fig. 1) by requiring
CLptrue ¼ pobserved; ð4Þ
min ptrueð Þ≥ 0; max ptrueð Þ≤ 1; ð5Þ
where pobserved and ptrue are the observed and true peak sizes, respectively.
Resulting allele profiles were imported into a database for further analysis.
Validation of ReFrame was performed in three steps: first, DNA of colonic
normal tissue was used to determine baseline deviations of the method in negative
controls (Supplementary Fig. 1). In addition, microsatellite-stable cell line DNA
(HT29) was used as a control. Finally, three cell line DNAs with differing mutation
states (HT29 displaying wild-type peak patterns, LS180 and RKO, displaying
mutant peak patterns) were mixed in 10% steps and expected allele distributions
were compared to the ReFrame results (Supplementary Figs. 1 and 7).
Selection of cMS and frameshift peptide sequences. For MHC ligand predic-
tion, 524 frameshift peptide sequences from 262 mononucleotide changes were
retrieved from SelTarbase (Version 201307, www.seltarbase.org)27. From an initial
series of 558,000 coding mononucleotide repeats, all candidates with a length of at
least eight bases were included. In particular cases, other cMS representing putative
driver genes, as well as genes which give rise to frameshift peptides with predicted
high affinity ligands according to the literature, were also added to the study. In
order to also assess potential epitopes located at the junction between N-terminal
wild type and C-terminal mutant peptide sequences, the tested peptide sequences
all comprised eight wild-type amino acids directly located upstream of the fra-
meshift peptide sequence to encompass possible fusion epitopes. The whole list of
used frameshift peptides is given in Supplementary Data 1.
HLA typing. Normal tissue DNA isolated from FFPE CRC blocks was genotyped
for HLA-A*02:01 status by Sanger sequencing using specific oligonucleotide pri-
mers for the amplification of a region spanning the 5′ end of exon 2 of the HLA-A
locus with an upstream intronic region. This region encompasses a single-nucleotide
variant that allows to distinguish HLA-A*02 from non-HLA-A*02 genes40 and thus
high accuracy classification of samples as HLA-A*02:01 positive or HLA*02:01
negative72. For amplification, the following oligonucleotide primers were designed
according to a protocol published in ref. 41: A2-2F: 5′-TCTCAGCCACTCCTCGT
C-3′, G-R: 5′-TGTCGAACCGCACGAACTG-3′. After amplification according to
ref. 41, Sanger sequencing was performed, and the nucleotide at nucleotide position
78 of the HLA-A gene locus (reference sequence NM_001242758.1) was used for
classification, GCTCYCACT with T indicating HLA-A*02:01 and C indicating non-
HLA-A*02:01. The method was successfully validated in independent specimens
with known HLA type. For B2M mutation analysis, the following oligonucleotide
primers were used: exon 1 forward, 5′-GGCATTCCTGAAGCTGACA-3′, exon 1
reverse, 5′-AGAGCGGGAGAGGAAGGAC-3′ (annealing temperature 59 °C); exon
2A forward, 5′-TTTTCCCGATATTCCTCAGGTA-3′, exon 2A reverse, 5′-AAT
TCAGTGTAGTACAAGAG-3′ (annealing temperature 57 °C); exon 2B forward,
5′-CATTCAGACTTGTCTTTCAG-3′, exon 2B reverse, 5′-TTTCAGCAGCTTA
CAA-3′ (annealing temperature 64 °C)37.
MHC ligand predictions. For MHC ligand prediction, the frameshift peptide
sequences derived from each the M1 and M2 mutated alleles were analyzed for the
presence of binders using the publicly available prediction tool NetMHCpan 4.0
(www.cbs.dtu.dk/services/NetMHCpan/)9, whose performance has been evaluated
to be one of the best of the available tools55. As m1- and p2-induced M1 frameshift
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peptides (akin to m2- and p1-induced M2 frameshift peptides) are identical, except
for one additional amino acid at the transition between wild type and neo-
sequence, we only used M1/m1 and M2/m2 frameshift peptides for MHC ligand
prediction.
Predicted epitopes were subdivided into three classes based on commonly used
thresholds. While the first class included epitopes with a predicted affinity of IC50
< 50 nM, referred to as high-affinity binders, the second class included all predicted
binders <500 nM (low-affinity binders). The last class contained all putative
epitopes with <5000 nM affinity (very low-affinity binders). All potential HLA
binders with an affinity >5000 nM were discarded. The peptide length of interest
was set to 8-mer to 14-mer peptides. A preselection of HLA supertype
representatives including HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-
A*24:02, HLA-A*26:01, HLA-B*07:02, HLA-B*08:01, HLA-B*27:05, HLA-
B*39:01, HLA-B*40:01, HLA-B*58:01, and HLA-B*15:01 was chosen based on
previous recommendations31,32. All selected cMS and frameshift peptide sequences
were submitted to a Python driver script operating NetMHCpan 4.09 to predict
putative MHC ligands. The prediction results were processed using a Python script
applying the above-mentioned IC50 thresholds to all predicted peptides, yielding
three datasets of peptides with potential very low, low, and high HLA binding
affinity. The resulting datasets were then used to generate figures visualizing the
predicted epitopes using matplotlib73. To that end, predicted epitopes were counted
and mapped for each HLA type, frameshift peptide candidate, and the respective
epitope class (high-, low-, or very low-affinity binder). The results of that analysis
were used to generate heat maps per candidate and HLA type using another
Python script available on github (see below).
Selection of HLA allele frequency data. HLA allele frequency datasets were
selected from the Allele Frequency Net Database34 by taking the largest datasets of
each ethnicity with at least 10,000 data points and sufficient resolution in HLA
alleles. These were further processed together with epitope and mutation data to
compute the immunological scores.
Computation of immunological scores. For all candidate frameshift peptides,
measures of probable immunological relevance were computed based on the above-
described predicted IC50 values and mutation frequencies. A hierarchy of prob-
abilities for the given candidates to produce immune reactions was computed,
including an epitope likelihood score (ELS) per HLA type, a GELS comprising all
HLAs under consideration, as well as an IRS. The ELS was defined to describe the
probability of a given frameshift neoantigen to be effective across a population,
relative to a single HLA:
ELSH nð Þ ¼ 1 1 fHð Þ2
   1 1 pbinding
  EH ðnÞj j 
; ð6Þ
where H 2 HLA supertypes is a given HLA, n 2 cMS is a given frameshift peptide,
fH the allele frequency of a given HLA allele, pbinding the probability, that a given
predicted epitope is actually bound, that is the true positive rate of the prediction
algorithm, and EH(n) the set of all epitopes predicted for a given HLA and fra-
meshift peptide. Taken together, ELSH constitutes the probability of a given can-
didate n having at least one MHC ligand for an HLA H and a random person from
a given population having at least one allele of H.
Consequently, the GELS gives the probability of a candidate n having at least
one MHC ligand among all HLAs, for which the given HLA is also present in a
randomly selected individual:
GELSX nð Þ ¼ 1
Y
H2HLAX
1 ELSH nð Þð Þ; X 2 A;Bf g; ð7Þ
GELS nð Þ ¼ GELSA nð Þ þ GELSB nð Þ  GELSA nð Þ  GELSB nð Þ; ð8Þ
where HLAX is the set of HLA types considered for locus X.
Finally, the IRS is the joint probability of a given frameshift peptide and its
underlying cMS mutation being present in an individual and at least one predicted
binder existing for an HLA present in that individual, assuming independence
between the presence of HLA alleles and present frameshift peptides:
IRS nð Þ ¼ pmut nð Þ  GELSðnÞ: ð9Þ
ELS and GELS were computed for all candidate frameshift peptides and HLAs
considered using Python on the three output classes of epitope prediction, where
binding probabilities pbinding were incremented from 0% to 90% in steps of 10%.
HLA allele frequencies were obtained from the Allele Frequency Net Database34.
IRSs were computed for all candidates with available mutation frequency data.
Cluster analysis of mutation patterns. Frameshift mutation abundances (m4–p4)
for each gene and tumor sample were filtered for missing data. For all subsequent
clustering experiments, missing values were replaced by the dataset mean. Abun-
dances of frameshift mutations were summarized by their respective reading frame
(M2, M1, wt), providing the features used for all subsequent analyses. Resulting
features were grouped by tumor sample and candidate cMS, respectively. Hier-
archical clustering using Ward’s minimum variance linkage74 was performed for
both feature sets grouped by cMS and tumors for all tumor samples considered, as
well as for cMS features considering only B2M-wild-type and mutated tumors,
respectively. Three clusters of candidate cMS were extracted from hierarchical
clustering both for features considering all tumor samples and features considering
B2M-wild-type tumors only.
Vaccination of A2.DR1 mice. A2.DR1 mice, provided by the Institute Pasteur
(Paris, France), are transgenic for HLA-A*02:01 and HLA-DRB1*01:01 and lack
all murine MHC molecules through knockout of β2m, H-2Db, and the whole MHC
class II locus44. All animal procedures followed the institutional laboratory animal
research guidelines and were approved by the governmental authorities (Regier-
ungspraesidium Karlsruhe, Abteilung 3 - Landwirtschaft, Ländlicher Raum,
Veterinär- und Lebensmittelwesen, approval number G302/19).
For the experiments, mice were assigned to the age- and sex-matched groups.
The M1 peptides LTN1 KKKMVRLDLLMRYLKAIKRMKNVYLQKERRL, MA
RCKS SNETPKKKRSAFPSRSLSS, MYH11.1 APGEETRPLSFLLEGLEDVELLKM
QMVLRRKRT, MYH11.2 MVLRRKRTLETQTSMEPRPVNKQLSTVLHHGK,
SLC22A9.1 VKGSPSCPLRDLQTLWPILALISMSSIWGT, SLC22A9.2 SMSSIWGT
MFSCCRLSLVQSSSWPTVLHLG,
SLC35F5 VAKISFFFALCGFWQICHIKKHFQTHKLL, TCF7L2 CGPCRRKK
SAFATYKVKAAASAHPLQMEAY, and p16INK4a LPNAPNSYGRRPIQVMMM
GSARVAELL were synthesized by the GMP & T Cell Therapy Unit at German
Cancer Research Center Heidelberg and the peptides CASP5 KQLRCWNTWAK
MFFMVFLIIWQNTMF and TGFBR2 KCIMKEKKSLVRLSSCVPVALMSAMTTS
SSQKNITPAILTCC were synthesized by Genaxxon bioscience GmbH including
high-performance liquid chromatography purification and quality control by mass
spectrometry. Due to the length of the M1 frameshift peptides, MYH11 and SL
C22A9 were synthesized in two parts each (MYH11.1, MYH11.2, SLC22A9.1, and
SLC22A9.2). The lyophilized peptides were dissolved in 100% dimethylsulfoxide
(SERVA Electrophoresis) at a concentration of 20 mg/ml and stored at −20 °C.
Mice were immunized intradermally three times in 7-day intervals. For each
immunization, a pool of 3–4 peptides (100 µg each) was injected per group together
with 20 µg CpG ODN 1826 (TIB MolBiol) as adjuvants in a phosphate-buffered saline
(PBS)-based solution (Thermo Fisher Scientific). Readout experiments were performed
7 days after the last immunization. The p16INK4A peptide was used as positive
control for the induction of an HLA-A*02:01-specific, cellular immune response75.
IFNɣ ELISpot. The spleen was removed aseptically, pressed through a 40-µm cell
strainer (Falcon), treated with Red Blood Cell lysis buffer (Sigma-Aldrich) to lyse
erythrocytes, and washed with RPMI Medium 1640 supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (all Thermo
Fisher Scientific). Ethanol-activated MultiScreenHTS plates (Merck) were coated
with purified rat anti-mouse IFNɣ antibody (clone R4-6A2, BD Bioscience) in PBS
and blocked with RPMI Medium 1640 containing 10% FBS, 100 U/ml penicillin,
and 0.1 mg/ml streptomycin. Splenocytes were seeded at 1 × 106 cells/well and
stimulated with 0.1 µg/ml peptide. Concanavalin A (Thermo Fisher Scientific) at
the same concentration was used as an assay high control for IFNɣ production.
After 20 h of incubation, IFNɣ-producing cells were detected with a biotinylated rat
anti-mouse IFNɣ antibody (clone XMG1.2, BD Bioscience), AKP Streptavidin (BD
Bioscience), and BCTP/NBT as a substrate (Thermo Fisher Scientific) for color
development. The CTL ImmunoSpot Reader (Cellular Technology Ltd) was used
for quantification of spots.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data underlying Figs. 2c and 5c and Supplementary Figs. 2, 3, 5, and 7 are
provided as a Source Data file. The Source data folder contains also the plots depicting
predicted HLA-binding peptides for all frameshift peptides and HLA alleles (underlying
Fig. 3). Mutation data used for candidate selection are available from SelTarbase [www.
seltarbase.org]. All remaining relevant data are available in the article, supplementary
information, or from the corresponding author upon reasonable request. Source data are
provided with this paper.
Code availability
The source code of all used algorithms can be accessed on GitHub [https://github.com/
atb-data/neoantigen-landscape-msi].
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